Pfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency med
Pfizer’s bid to buttress its presence in a pediatric rare disease has hit a snag, giving competitor Acendis Pharma a longer runway to gather speed with a newly approved treatment.
Source: fiercepharma.com